NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OMER
Omeros Corporation
There isn't enough reported data to score OMER yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OMER Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
OMER's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over OMER in the historical PE scenario, which offers more potential upside but is not a forecast.
OMER PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1x | $1.76 | -90% |
| Fair | 5.3x | $9.22 | -49% |
| Forward | 5.5x | $17.99 | — |
| Expensive | 10x | $17.82 | -1% |
| Current | 10x | $17.99 | — |
Historical ranges are pointers, not guarantees.
OMER's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OMER Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OMER to return to profit, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OMER on earnings, with more consistent year-over-year improvement.
OMER Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.25 | +88% |
| Q2 2026 | $1.73 | +$3.84 |
| Q1 2026 | $1.15 | +$3.80 |
| Q4 2025 | -$0.05 | +$2.65 |
| Q3 2025 | -$2.02 | +$0.28 |
| Q2 2025 | -$2.11 | +$0.23 |
| Q1 2025 | -$2.65 | -$0.69 |
| Q4 2024 | -$2.70 | -$0.83 |
| Q3 2024 | -$2.30 | -797% |
OMER has returned to profit: it earned $1.73 per share over the past year, after losing money the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
OMER has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus up 35% for OMER.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OMER on profitability, with a higher operating margin.
OMER Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $30M | +15% |
| Q2 2021 | $28.8M | +113% |
| Q1 2021 | $21.1M | -11% |
| Q4 2020 | $10.6M | -68% |
| Q3 2020 | $26.1M | -13% |
OMER's revenue is growing: $29M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.3% | N/A |
| Q1 2026 | -176% | N/A |
| Q3 2021 | -61% | +37 points |
| Q2 2021 | -83% | +121 points |
| Q1 2021 | -145% | -45 points |
| Q4 2020 | -318% | -247 points |
| Q3 2020 | -97% | -60 points |
| Q2 2020 | -205% | N/A |
OMER's operating margin was 0.3% last quarter, up 146 points from the same quarter a year ago, near the top of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over OMER on cash generation, producing positive trailing cash flow while its opponent burns cash.
OMER Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.1M | +$26.1M |
| Q1 2026 | -$14.5M | +$21.4M |
| Q4 2025 | -$39.8M | -$10.8M |
| Q3 2025 | -$18.5M | +$13.6M |
| Q2 2025 | -$22M | +$24.1M |
| Q1 2025 | -$35.9M | +$6M |
| Q4 2024 | -$29M | +$5.9M |
| Q3 2024 | -$32.1M | +$621K |
OMER has burned cash in almost every quarter: −$69M over the past year, against −$119M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OMER on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OMER Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -491K shares |
| 1 year | +53% | +31M shares |
| 3 years | +43% | +26.8M shares |
| 5 years | +44% | +27.3M shares |
| Available history | +82% | +40.3M shares |
OMER has 90M diluted shares, up 53% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $5.7M |
| Q1 2026 | $4.2M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OMER spent $10M buying back its own shares over the past year, after none the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OMER Net Leverage
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OMER Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.2 | Neutral |
| Stochastic | 62.7 | Neutral |
OMER's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OMER PE vs Healthcare Sector
| Metric | OMER | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 85 | 29 | 56 pts above |
OMER has the edge over NVO on valuation relative to its sector.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OMER Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.1 | 0.5% below |
| 20 week MA | $16.0 | 13% above |
| 50 week MA | $13.4 | 34% above |
| 100 week MA | $9.89 | 82% above |
| 200 week MA | $7.06 | 155% above |
OMER has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
OMER Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $14.9 | -0.7% |
| 2021 | $14.9 | $7.64 | -49% |
| 2022 | $7.64 | $2.54 | -67% |
| 2023 | $2.54 | $3.27 | +29% |
| 2024 | $3.27 | $11.7 | +257% |
| 2025 | $11.7 | $15.7 | +35% |
| 2026 YTD | $15.7 | $18.0 | +15% |
OMER has the edge over NVO on returns for 2026, with the stronger performance.